Artivion, Inc. (AORT)
Market Cap | 1.20B |
Revenue (ttm) | 384.90M |
Net Income (ttm) | -728,000 |
Shares Out | 41.92M |
EPS (ttm) | -0.03 |
PE Ratio | n/a |
Forward PE | 276.06 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 370,087 |
Open | 29.50 |
Previous Close | 28.98 |
Day's Range | 27.12 - 29.50 |
52-Week Range | 13.18 - 30.00 |
Beta | 1.75 |
Analysts | Strong Buy |
Price Target | 31.00 (+7.98%) |
Earnings Date | Nov 7, 2024 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shel... [Read more]
Financial Performance
In 2023, Artivion's revenue was $354.00 million, an increase of 12.82% compared to the previous year's $313.79 million. Losses were -$30.57 million, 60.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $31.0, which is an increase of 7.98% from the latest price.
News
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Ch...
Artivion Reports Third Quarter 2024 Financial Results
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP cons...
Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results...
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfu...
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief ...
Artivion Reports Second Quarter 2024 Financial Results
Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency ...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial result...
Artivion Amends Agreements with Endospan
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $...
Data-Driven Growth Fuels More Upside For Overlooked Artivion
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval...
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Fin...
Artivion Reports First Quarter 2024 Financial Results
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP con...
Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day D...
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial result...
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the ...
Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the...
Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript
Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript
Artivion Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis an...
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results
ATLANTA , Feb. 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 fin...
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections...
Artivion Obtains $350 Million in Senior Secured Credit Facilities
Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc. ...
Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.
Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease t...
Artivion Announces Completion of Enrollment in PERSEVERE Trial
ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PE...
Artivion, Inc. (AORT) Q3 2023 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Offic...
Artivion Reports Third Quarter 2023 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 1...